A shared genetic signature for common chronic pain conditions and its impact on biopsychosocial traits

Scott F. Farrell PhD[1,2,3], Pik-Fang Kho PhD[4,5,6], Adrián I. Campos PhD[7], Miguel E. Rentería PhD[8], Rutger M. J. de Zoete PhD[9], Michele Sterling PhD[1,2], Trung Thanh Ngo PhD[1,10†] & Gabriel Cuéllar-Partida PhD[10†*]

Author affiliations:

1. RECOVER Injury Research Centre, The University of Queensland, Herston QLD, Australia

2. NHMRC Centre of Research Excellence: Better Health Outcomes for Compensable Injury, The University of Queensland, Herston QLD, Australia

3. Tess Cramond Pain & Research Centre, Royal Brisbane & Women's Hospital, Herston QLD, Australia

4. Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford CA, USA

5. Molecular Cancer Epidemiology Laboratory, Department of Genetics & Computational Biology, QIMR Berghofer Medical Research Institute, Herston QLD, Australia

6. School of Biomedical Sciences, Queensland University of Technology, Brisbane QLD, Australia

7. Institute for Molecular Bioscience, The University of Queensland, St Lucia QLD, Australia

8. Genetic Epidemiology Laboratory, Department of Genetics & Computational Biology, QIMR Berghofer Medical Research Institute, Herston QLD, Australia

9. School of Allied Health Science and Practice, The University of Adelaide, Adelaide SA, Australia

10. Diamantina Institute, The University of Queensland & Translational Research Institute, Woolloongabba QLD, Australia

† These authors contributed equally to this work

* Current address: 23andMe Inc., Sunnyvale CA, United States of America

Correspondence to:

Dr Scott Farrell

RECOVER Injury Research Centre — Surgical, Treatment & Rehabilitation Service (STARS | Level 7), 296 Herston Rd, Herston QLD 4029, Australia.

E: Scott.Farrell@uq.edu.au | P: +61 7 334 64791 | F: +61 7 334 69136

Dr Trung Ngo

RECOVER Injury Research Centre — Surgical, Treatment & Rehabilitation Service (STARS | Level 7), 296 Herston Rd, Herston QLD 4029, Australia.

E: Trung.Ngo@uq.edu.au | P: +61 42 111 7258

Running Title: Biopsychosocial genetic signature of chronic pain

Abstract

Background: The multifactorial heterogenous nature of chronic pain with its multiple comorbidities presents a formidable challenge in disentangling the aetiology underlying patient symptoms.

Methods: Here, we performed genome-wide association studies (GWAS) of eight regional chronic pain types using UK Biobank data (N=4,037–79,089 cases; N=239,125 controls), followed by bivariate linkage disequilibrium-score regression and latent causal variable analyses to determine (respectively) their genetic correlations and genetic causal proportion (GCP) parameters with 1,492 other complex traits.

Findings: We report evidence of a shared genetic signature across several common chronic pain types as their genetic correlations and causal directions were broadly consistent across a wide array of biopsychosocial traits. Furthermore, we identified 5,942 significant genetic correlations, of which 570 trait pairs showed evidence of a causal association ($|GCP| > 0.6$; 5% false discovery rate), including 488 traits contributing to chronic pain while 82 were affected by pain. A range of somatic pathologies (e.g., musculoskeletal, visceral), psychiatric traits (e.g., depression, trauma, anxiety, mania, bipolar disorder), socioeconomic factors (e.g., occupation) and other medical comorbidities (e.g., cardiovascular disease) contributed to an increased risk of regional chronic pain. Conversely, each chronic pain type contributed to various other traits such as increased medication use (e.g., analgesics) and increased risk of ischaemic heart disease & depression.

Interpretation: This data-driven study — through comprehensive analysis of the many conflicting factors in chronic pain — has delineated a common genetic basis and underlying genetic causal relationships. Furthermore, it demonstrates a novel & efficient strategy for sharpening the prevailing biopsychosocial model of chronic pain disorders — such as enhancing the design of

interventional trials targeting identified underlying causal factors — to help accelerate the development of more effective treatments with broader clinical utility.

*Funding***:** Australian Government Research Training Program Scholarship.

Research in Context Panel

Evidence before this study

Previous work examining the genetic bases of chronic pain conditions and associated traits including candidate gene, twin and genome-wide association studies (GWAS) have been limited in scope and scale — based on PubMed, MedRxiv & BioRxiv searches (from inception to 16 March 2022) using the terms "pain" and "genetic" with no language restrictions. Therefore, a comprehensive delineation of genetic causal direction across several common chronic pain conditions and biopsychosocial traits would address a major evidence gap in rheumatology, pain & rehabilitation medicine and many allied fields.

Added value of this study

By leveraging UK Biobank and several other large-scale GWAS datasets including >1400 biopsychosocial factors, we provide evidence for a shared genetic signature across common chronic pain types. This novel finding suggests an increased genetic risk in developing multiple chronic pain types. This study also provides genetic evidence with >5900 significant genetic correlations to support phenotypic associations widely observed in previous clinical pain studies. Furthermore, it has characterised the multidimensional casual traits by narrowing down a range of genetically supported risk and protective factors for chronic pain, which lays the foundation for translational studies to identify causal genetic variants and pathophysiological pathways for developing novel diagnostic & therapeutic strategies.

Implications of all the available evidence

A shared genetic signature across chronic pain conditions supports a universal/conserved core upon which to focus interventions for more durable therapeutic effectiveness and broader clinical utility, alongside genetically stratified patient subtyping strategies. For instance, the precedent for genetically supported therapeutic (drug) targets & mechanisms suggests further interrogation of the complex traits identified in our study — through interventional trials targeting such causal factors — may help to accelerate the clinical validation of novel effective treatments for common chronic pain conditions.

Introduction

Despite enormous research efforts into determining the aetiology of chronic pain, common musculoskeletal conditions such as back pain and neck pain remain a major clinical and scientific challenge. Over the past decade however, large-scale genome-wide association studies (GWAS) have made inroads towards elucidating the biological pathways and complex traits contributing to a wide range of conditions such as neurological, psychiatric and cardiometabolic disorders.[1] While such studies have provided evidence for genetically supported therapeutic targets and mechanisms,[2,3] the application of statistical genetics methods to rheumatological[4-7] and chronic pain conditions[8-10] as a strategy towards disentangling their causal mechanisms requires further comprehensive and concerted effort.

Previous clinical and epidemiological studies have found a range of psychiatric, lifestyle and socioeconomic factors associated with an increased risk of chronic pain,[11] while medical conditions such as obesity and cardiovascular diseases are also common comorbidities.[11] Large-scale GWAS have identified specific genetic loci in chronic pain conditions (e.g., back pain[9] & widespread pain[10]) and demonstrated shared genetic bases with biopsychosocial traits (e.g., depression[9,10,12]). However, the nature of causal relationships between common chronic pain conditions and such multidimensional factors remains to be comprehensively examined.

Here we investigated the genetic correlations & causal relationships between eight types of regional chronic pain and a comprehensive range of biological, psychological/psychiatric and social traits. In the largest phenome-wide study of chronic pain to date, we leveraged GWAS summary statistics in the Complex Traits Genetics Virtual Lab (CTG-VL — http://genoma.io)[13]

to delineate the putative genetic causal directions across common chronic pain conditions and >1,400 other traits/disorders.

Methods

Discovery GWAS Datasets for Chronic Pain

An overview of the analysis pipeline employed in the present study is shown in Figure 1. We performed GWAS of regional chronic pain types using the UK Biobank resource (application number 25331). The UK Biobank holds research ethics approval from the North West Multi-centre Research Ethics Committee (Manchester, United Kingdom). All participants provided written informed consent.

Chronic pain was defined using self-report answers to the following questions: *Have you had [back pains / neck or shoulder pains / hip pains / knee pains / abdominal pains / facial pains / headaches / pain all over the body] for more than 3 months?* (Questionnaire field ID: 6159). These questions could be answered with *Yes*, *No*, *Don't know*, or *Prefer not to answer*. Participants who responded *Yes* to a question were defined as cases for that specific chronic pain type (i.e., chronic back pain, chronic widespread pain [pain all over the body] etc.). We defined controls as participants who denied experiencing any pain for more than three months (N=239,125). Participants who preferred not to answer were excluded from the study. Sample sizes of each GWAS were as follows: back pain (N=79,089); neck/shoulder pain (N=72,216); hip pain (N=41,677); knee pain (N=77,996); abdominal pain (N=21,285); facial pain (N=4,037); headache (N=39,283); widespread pain (N=6,063). Sample characteristics are further detailed in Supplementary Table S1.

We performed GWAS using REGENIE (v1·0·6·2)[14] to test associations between the chronic pain types and genetic variants. REGENIE is a GWAS method that implements a logistic mixed model, whereby a genetic relationship between individuals is modelled as a random effect to account for cryptic relatedness. Covariates for the association analysis comprised sex, age, genotyping array and the top 10 principal components derived from genetic data. We used quality control procedures comprising exclusion of variants with: **(i)** minor allele frequency (MAF) < 0·005; **(ii)** imputation quality < 0·6; and **(iii)** deviation from Hardy-Weinberg equilibrium (P-value < 1×10^{-5}). Subsequently, 11,172,285 single nucleotide polymorphisms (SNPs) remained for analysis. Participant data were excluded if their genotype-derived principal components 1 and 2 were more than six standard deviations from those of the 1000 Genomes European population. Following quality control, up to 441,088 participants remained in the GWAS.

Genetic Correlations

Genetic correlations were estimated between the regional chronic pain types and a wide range of other complex traits. Cross-trait bivariate linkage disequilibrium (LD) score regression was used — a method that leverages the expected relationship between LD and GWAS association statistics to estimate genetic correlations across traits while accounting for potential sample overlap across studies,[15] as implemented in CTG-VL.[13] CTG-VL is a publicly available web platform compiled with >1,490 GWAS summary statistics that is used for running analyses across a comprehensive range of complex traits & disorders (mostly from UK Biobank releases). CTG-VIEW (https://view.genoma.io) is a data aggregator that enables direct queries, visualisations and storage of VL analysis results (and that from other data resources).

A genetic correlation (rG) ranges from -1 to 1 and quantifies the genome-wide genetic concordance between a pair of traits. Genetic correlation estimates approaching 1 or -1 indicate (respectively) that a proportion of genetic variants have concordant or divergent effects on both traits. Conversely, a genetic correlation that approaches 0 indicates there is little genetic concordance between the traits or that the genetic predictors of the traits are largely independent. A Benjamini-Hochberg false discovery rate (FDR < 5%) procedure was applied to genetic correlations between complex traits and each chronic pain type GWAS to account for multiple testing.

Latent Causal Variable Analyses

For trait pairs with non-zero genetic correlation (FDR < 5%), we employed latent causal variable (LCV) analyses to determine if the genetic correlation reflected a causal relationship or horizontal pleiotropy by estimating genetic causal proportion (GCP).[16,17] The LCV method is robust to horizontal pleiotropy, which is ubiquitous in complex traits. LCV analyses can be conceptualised as assuming a latent 'causal' variable that mediates the genetic correlation of two traits. Using mixed fourth moments of the bivariate effect size distribution across all SNPs in both GWAS, LCV estimates the posterior mean for GCP, which indicates the degree to which one trait is correlated with the latent 'causal' variable. GCP estimates range from -1 to 1: high positive values (GCP > 0·6) indicate greater partial genetic causality for Trait A (i.e., a chronic pain type) on Trait B (i.e., biological / psychological / social trait); whereas negative values (GCP < -0·6) indicate greater partial genetic causality for Trait B on Trait A. That is, GCP > 0·6 indicates that chronic pain likely has a causal effect on another particular trait, whereas GCP < -0·6 indicates a particular trait likely has a causal effect on chronic pain. Benjamini-Hochberg false discovery rate (FDR < 5%) was applied across GCPs for complex traits with each chronic pain type GWAS.

Role of the Funding Source

The study funding sources had no role in study design; collection, analysis, and interpretation of data; writing the report; and decision to submit the paper for publication.

Results

Genetic Correlations & Latent Causal Variable Analyses

For each of the eight chronic pain types, details of significant genetic correlations with putative causal relationships are summarised in Figures 2–8 and Supplementary Figures S1 & S2, while rG and GCP data are reported in Supplementary Tables S2–S9. Complete genetic correlation and LCV analysis results for all 1,492 traits are presented in Supplementary Tables S10–S17.

From 11,932 trait pairs, we identified 5,942 significant genetic correlations (which corroborate many reported phenotypic associations from previous clinical studies), of which 570 trait pairs showed evidence of a causal association ($|GCP| > 0.6$; 5% false discovery rate). Of these, 488 traits had genetic casual effects on chronic pain, while the remaining 82 traits were affected by pain.

Comparisons of rG and significant GCP results across the eight chronic pain types are presented in Figures 2 & 3. Overall, the direction of the genetic correlations between the complex traits and chronic pain were broadly consistent across all eight types. There were eight instances where the direction of genetic causal relationships (denoted by GCP > 0.6 or < -0.6) differed between the chronic pain types (Supplementary Table S18). Additional rG estimates for the eight chronic pain

types are presented in Supplementary Table S19, including significant genetic correlations between each type, whereby the analysis method accounted for the overlapping samples.

Key Results Across Chronic Pain Types

Significant *rG* (5% FDR) and GCP estimates (< -0.6; 5% FDR) were observed for musculoskeletal pathologies, which showed genetic causal effects on chronic back, neck/shoulder, hip, knee, abdominal, headaches and widespread pain, including local sites (e.g., coxarthrosis of the hip & chronic hip pain *rG* [S.E.] = 0·42 [0·06]; GCP [S.E.] = -0·90 [0·08]) as well as remote sites (e.g., other intervertebral disc disorders & chronic knee pain *rG* [S.E.] = 0·61 [0·12], GCP [S.E.] = -0·79 [0·16]) (Figures 4–8, Supplementary Figures S1 & S2, Supplementary Tables S2–S9). Cardiovascular disease-associated traits affected each of the chronic pain types (e.g., heart failure contributes to back pain [*rG* (S.E.) = 0·22 (0·09); GCP (S.E.) = -0·73 (0·16)] and hip pain [*rG* (S.E.) = 0·30 (0·11); GCP (S.E.) = -0·62 (0·24)]), while certain chronic pain types (i.e., neck/shoulder, abdominal, facial & widespread pain) also affected cardiovascular traits such as ischaemic heart disease (neck/shoulder pain *rG* [S.E.] = 0·30 [0·04], GCP [S.E.] = 0·71 [0·22]; facial pain *rG* [S.E.] = 0·26 [0·09], GCP [S.E.] = 0·64 [0·22]). A number of chronic pain types (i.e., back, neck/shoulder, hip, knee, abdominal & headaches) contributed to medication use for cholesterol, blood pressure, diabetes or exogenous hormones. Chronic headaches and widespread pain also impacted the use of analgesics (i.e., paracetamol, ibuprofen, aspirin; and paracetamol, respectively), while the use of various medications (e.g., analgesics, cardiovascular drugs) affected chronic back, neck/shoulder, hip, knee, abdominal, headache and widespread pain.

Psychological traits and psychiatric diagnoses also had genetic causal effects on chronic pain types. Notably: **(i)** depression and anxiety-associated traits increased the risk of chronic back, neck/shoulder, hip, knee, abdominal, headache and widespread pain; **(ii)** mania-associated traits increased the risk of chronic back, neck/shoulder, hip, knee, facial and widespread pain; and **(iii)** substance abuse/addiction-associated traits increased the risk of chronic back, neck/shoulder, hip, knee, abdominal, facial and widespread pain. Traits concerning bipolar disorder and psychosis respectively increased the risk of hip, knee and widespread pain; and of neck/shoulder, knee and facial pain. Chronic back pain, facial pain and headaches had genetic causal effects upon traits concerning depression, anxiety and mania (significant rG [5% FDR] and GCP > 0·6 [5% FDR]). Traits specific to occupations demonstrated genetic causal contributions to back, neck/shoulder, hip, knee, abdominal and widespread pain (e.g., receptionist & chronic back pain rG [S.E.] = 0·38 [0·17]; GCP [S.E.] = -0·97 [0·04]), while traits relating to work environment increased the risk of all eight chronic pain types (e.g., *'Workplace had a lot of diesel exhaust: Often'* and chronic widespread pain rG [S.E.] = 0·60 [0·15]; GCP [S.E.] = -0·81 [0·15]).

Region Specific Summaries

Additional results on the key findings for each pain type are presented in the Supplementary Results.

Discussion

The multifactorial and dynamic nature of chronic pain conditions means that assessing aetiological relationships is particularly challenging due to the large sample sizes and long follow-up

timeframes required for multivariate longitudinal analyses. Large-scale genetic datasets adequately powered for GWAS along with statistical genetics methods developed for investigating causality (e.g., LCV, Mendelian randomization [MR]) present a way forward. The primary findings of this data-driven study provide quantitative genetic evidence for a range of shared biopsychosocial factors demonstrating causal effects upon eight common types of chronic pain. Certain clinical factors (e.g., musculoskeletal pathology, medical comorbidities), psychological/psychiatric traits (e.g., depression, trauma, anxiety, mania) and socioeconomic factors (e.g., occupation) increased the risk of chronic pain types. The results also indicated genetic causal effects of chronic pain upon other traits such as increased medication use and an increased risk of cardiovascular disease and depression. The current study has characterised the multidimensional casual traits and substantially narrowed down the range of genetically supported risk and protective factors for chronic pain. This work lays the foundation for further translational studies to identify the underlying causal genetic variants and pathophysiological pathways for developing novel diagnostic and therapeutic strategies and technologies[7].

Overall, the directions of genetic correlations were consistent across an array of biopsychosocial traits and common chronic pain types. The vast majority of significant genetic causal directions between them were also consistent, while only a small minority differed across the chronic pain types — which suggests an underlying universal genetic core that is shared with these complex traits. In addition, significant genetic correlations found between each of the eight chronic pain types provides further evidence of a shared genetic signature, which builds upon recent studies[4,18] and earlier proposals[19] pursuing this otherwise elusive empirical demonstration. Moreover, the biopsychosocial traits identified in our study represent candidates for patient classification, risk

stratification and pain phenotyping in the clinical management of chronic pain conditions.[6] Based on the precedent for genetically supported therapeutic targets,[2,3] the identified traits with genetic causal effects also represent potential targets in the clinical management of chronic pain, as our results provide corroborating genetic evidence for current treatment and prevention strategies (e.g., respectively, weight-loss in knee osteoarthritis[20] & targeting post-traumatic stress after injury[21,22]).

Our results provide corroborating genetic evidence that musculoskeletal pathologies (e.g., intervertebral disc disorders in back pain, spondylopathies in neck/shoulder pain, coxarthrosis in hip pain) and visceral pathologies (e.g., renal & ureteric calculi) contribute to chronic pain. We also found genetic causal effects of painful pathologies at remote sites upon regional chronic pain types (e.g., shoulder impingement on chronic hip pain), which is consistent with a shared genetic signature and associated predisposition to chronic pain (i.e., an underlying genetic predisposition to musculoskeletal shoulder pathology also contributes to increased risk of chronic hip pain). Similarly, facial pain demonstrated genetic evidence of contributing to nerve-related pathologies (including mononeuropathies & carpal tunnel syndrome), which may reflect genetic mechanisms in common between trigeminal neuralgia and other neuropathic pain conditions.

Not surprisingly, our results indicate that certain chronic pain types (i.e., headaches & widespread pain) contribute to the use of analgesic medications (i.e., paracetamol, ibuprofen, aspirin; and paracetamol, respectively). Interestingly, various drugs used in the treatment of pain (e.g., opioids, non-steroidal anti-inflammatory drugs, antidepressants[12]), cardiovascular disease (e.g., statins, beta-blockers) and gastro-oesophageal reflux showed an effect of increased risk for various chronic pain types. While some of these may reflect a genetic correlation between pain and

problematic opioid use,[23] the effect of medication use on increasing the risk of chronic pain may also be attributable to an indirect causal effect. For example, an unobserved trait (e.g., symptom or disease), which increases the likelihood of both medication use and a chronic pain type, could create an apparent casual effect between that medication and the pain type. That is, medication use (e.g., analgesics) could simply serve as a proxy for conditions that cause pain or that are commonly co-morbid with chronic pain. For instance, statins and beta-blockers may serve as proxies for cardiovascular disease, while antidepressants may reflect the relationship between chronic pain and depression,[12] or conversely, the use of antidepressants to treat chronic pain conditions.[24,25]

Our findings indicate that while pain conditions and psychological traits (e.g., depression) are frequently co-morbid at a phenotypic level, the pattern of causal relationships between them are heterogenous across the various chronic pain types. For instance, we observed genetic evidence of causal relationships across both directions between depression-associated traits and chronic headaches & back pain (i.e., a proportion of relationships are pain → depression and others are depression → pain [Supplementary Tables S2, S8]). In contrast, depression-associated traits exclusively showed effects on chronic neck/shoulder, hip, knee, abdominal and widespread pain (i.e., depression → pain only [Supplementary Tables S3–6, S9]), consistent with evidence for (modest) effects of treatments targeting depression upon pain & disability in such conditions (e.g., serotonin-noradrenaline reuptake inhibitors for knee osteoarthritis[25]). Conversely, chronic facial pain increased the risk of seeking care for depression (i.e., pain → depression only [Supplementary Table S7]). These findings are broadly consistent with other genetic studies of complex traits concerning depression and chronic pain, which have shown: **(i)** genetic correlations between depression-related traits and various pain conditions[9,26]; and **(ii)** genetic causal relationships

between chronic pain and depression, spanning both depression → pain pathways[26] and pain → depression pathways.[10,26] Taken together, the current study's results and previous findings[10,12,26] raise further intriguing hypotheses, such as either or both causal directions may exist on a patient sub-group basis,[24] which may even change over time as their condition/comorbidities further develop. Our LCV results also implicate a history of trauma or stress — including the death of a close relative in last two years; being adopted as a child; sexual assault; marital separation; and military service — as genetic causal factors for various chronic pain types. Phenotypic studies have previously reported that trauma or post-traumatic stress are risk factors for the development of chronic pain.[27] Our LCV results provide independent convergent evidence for targeting post-traumatic stress symptoms in the treatment of pain, such as recently reported in a randomised controlled trial of whiplash-associated disorder,[21] which showed reductions in pain & disability through improvements in stress, depression & post-traumatic stress.[22] In addition to depression and trauma, traits concerning anxiety, psychosis, bipolar disorder and mania showed genetic causal effects on several chronic pain types. Socioeconomic factors (particularly concerning occupation) also demonstrated genetic causal effects on a range of chronic pain types and are discussed further in the Supplementary Results. Broadly, traits associated with lower socioeconomic status had a genetic causal impact of increased chronic pain risk, which suggests that interventions and policies targeting socioeconomic inequality may have beneficial downstream effects on the community burden of chronic pain.

Various medical conditions such as cardiovascular, gastrointestinal, respiratory and haematological diagnoses demonstrated genetic correlations and genetic causal relationships with chronic pain types. Notably, cardiovascular-related traits showed heterogeneous associations. For

example, heart failure contributed to chronic back and hip pain, whereas neck/shoulder and facial pain increased the risk of ischaemic heart disease. Numerous cardiovascular risk factors showed genetic causal contributions to chronic pain such as obesity (i.e., hip, knee & widespread pain), low-density lipoprotein/Apolipoprotein B (i.e., back, neck/shoulder, hip & knee pain) and triglycerides (i.e., facial & widespread pain). These findings are consistent with phenotypic correlations between chronic pain and cardiovascular diagnoses & mortality, which may reflect other associations between chronic pain and cardiac risk factors (e.g., smoking).[11]

Strengths, Limitations & Further Research

The present study employed LCV analyses to delineate traits with evidence of genetic causal contributions across eight chronic pain types. From a total pool of >11,900 trait pairs, it was distilled down to <5% with the vast majority (488/570) showing genetic causal effects on chronic pain. This analytical strategy employing large-scale comprehensive data and statistical genetics methods for investigating causality has characterised a broad range of genetically supported risk and protective factors for common chronic pain types.

A limitation of the current study is the minimal clinical details used to define regional chronic pain, i.e., a self-report questionnaire regarding presence of pain for >3 months at a body site. However, this minimal phenotyping approach enables acquisition of large-scale data with sufficient power for GWAS and post-GWAS analyses of causal relationships. As the chronic pain and complex trait GWAS data were mostly derived from the UK Biobank, we employed LCV analyses rather than a more traditional approach (e.g., MR) because overlapping samples in the latter can bias estimates towards the confounded associations.[28] Although the LCV method is not

able to detect bidirectional relationships between two individual traits (e.g., chronic pain → Trait A and Trait A → chronic pain), its current data-driven application in comprehensive phenome-wide analyses — particularly for complex chronic disorders such as persistent pain — is an efficient & effective strategy upon which to follow up with traditional approaches (e.g., MR, genomic structural equation modelling[29]) targeting the genetic causal traits delineated in the current study.

Further work is required such as: **(i)** genetic epidemiology studies collecting data on more specific chronic pain diagnoses, clinical traits (e.g., pro- & anti-nociceptive phenotypes, medication/treatment responses[24]) and epigenetic factors (e.g., early life stress, physical activity); **(ii)** replication in other large genotyped datasets[4,9] and particularly population samples with non-European ancestry; and **(iii)** incorporating putative transdiagnostic subtypes and genetic risk stratification of placebo/control groups in randomised clinical trials of chronic pain interventions.[2,3,12,24,30]

Conclusion

Our LCV analysis of >1,400 biopsychosocial complex traits has leveraged the underlying genetic variant data to provide a comprehensive characterisation of the risk and protective factors across common regional chronic pain conditions, and in turn, testable hypotheses for further targeted interrogation. It has also provided corroborating genetic evidence for current treatment approaches (e.g., targeting psychological traits), which lays the foundation for further translational studies into developing more effective multidisciplinary care frameworks and enhancing patient outcomes.

Data Sharing Statement

Complex trait GWAS summary statistics are publicly available. Links to reference and download each of these are available in CTG-VL (https://vl.genoma.io) and CTG-VIEW (https://view.genoma.io). Complete GWAS summary statistics and results from downstream analyses for all the chronic pain types reported in the current study (Supplementary Table S1) are available at CTG-VIEW.

Funding

AIC was supported by a UQ Research Training Scholarship from The University of Queensland. PFK was supported by an Australian Government Research Training Program Scholarship from Queensland University of Technology (QUT). RECOVER Injury Research Centre (MS, SFF) receives unrestricted grant funding from the Motor Accident Insurance Commission (Queensland). The funders had no role in the design or interpretation of this study. This research was initially carried out at the Translational Research Institute (TRI), Woolloongabba, QLD 4102, Australia. TRI is supported by a grant from the Australian Government. SFF, TTN & GC-P conceived the study. TTN & GC-P co-supervised the study. SFF & TTN performed the literature search. AIC & MER performed the GWAS. SFF performed downstream analyses with support from GC-P. SFF prepared the figures with support from TTN & GC-P. All authors contributed to interpretation of results. SFF, TTN & GC-P wrote the manuscript with feedback from all coauthors.

Declaration of Interests

GC-P contributed to this study while employed at The University of Queensland. He is now an employee of 23andMe, Inc and may hold stock in the company.

References

1.   Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug repurposing. *Nature Reviews Genetics* 2021; **22**(10): 658-71.

2.   King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. *PLOS Genet* 2019; **15**(12): e1008489.

3.   Ginsburg GS, Cavallari LH, Chakraborty H, et al. Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. *Genetics Med* 2021; **23**(7): 1185-91.

4.   Boer CG, Hatzikotoulas K, Southam L, et al. Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations. *Cell* 2021; **184**(18): 4784-818.e17.

5.   Vincent TL. Of mice and men: converging on a common molecular understanding of osteoarthritis. *Lancet Rheumatol* 2020; **2**(10): e633-e45.

6.   Nijs J, George SZ, Clauw DJ, et al. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. *The Lancet Rheumatology* 2021; **3**(5): e383-e92.

7.   Fang H, Chen L, Knight JC. From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis. *The Lancet Rheumatology* 2020; **2**(1): e50-e62.

8.   Farrell SF, Campos AI, Kho PF, et al. Genetic basis to structural grey matter associations with chronic pain. *Brain* 2021; **144**(12): 3611–22.

9.   Freidin MB, Tsepilov YA, Palmer M, et al. Insight into the genetic architecture of back pain and its risk factors from a study of 509,000 individuals. *PAIN* 2019; **160**(6): 1361-73.

10.   Johnston KJA, Adams MJ, Nicholl BI, et al. Genome-wide association study of multisite chronic pain in UK Biobank. *PLoS Genet* 2019; **15**(6): e1008164.

11. Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. *Br J Anaesth* 2019; **123**(2): e273-e83.

12. Roughan WH, Campos AI, García-Marín LM, et al. Comorbid Chronic Pain and Depression: Shared Risk Factors and Differential Antidepressant Effectiveness. *Front Psychiatry* 2021; **12**: 643609.

13. Cuéllar-Partida G, Lundberg M, Kho PF, et al. Complex-Traits Genetics Virtual Lab: A community-driven web platform for post-GWAS analyses. *bioRxiv* 2019: 518027.

14. Mbatchou J, Barnard L, Backman J, et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nature genetics* 2021; **53**(7): 1097-103.

15. Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. *Nature genetics* 2015; **47**(11): 1236-41.

16. Haworth S, Kho PF, Holgerson PL, et al. Assessment and visualization of phenome-wide causal relationships using genetic data: an application to dental caries and periodontitis. *European Journal of Human Genetics* 2021; **29**(2): 300-8.

17. O'Connor LJ, Price AL. Distinguishing genetic correlation from causation across 52 diseases and complex traits. *Nature genetics* 2018; **50**(12): 1728-34.

18. Meng W, Adams MJ, Reel P, et al. Genetic correlations between pain phenotypes and depression and neuroticism. *European Journal of Human Genetics* 2020; **28**(3): 358-66.

19. Diatchenko L, Fillingim RB, Smith SB, Maixner W. The phenotypic and genetic signatures of common musculoskeletal pain conditions. *Nature Reviews Rheumatology* 2013; **9**(6): 340-50.

20.   Arden NK, Perry TA, Bannuru RR, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. *Nat Rev Rheumatol* 2021; **17**(1): 59-66.

21.   Sterling M, Smeets R, Keijzers G, Warren J, Kenardy J. Physiotherapist-delivered stress inoculation training integrated with exercise versus physiotherapy exercise alone for acute whiplash-associated disorder (StressModex): a randomised controlled trial of a combined psychological/physical intervention. *British Journal of Sports Medicine* 2019.

22.   Elphinston RA, Sterling M, Kenardy J, Smeets R, Armfield NR. The mechanisms of effect of a physiotherapist-delivered integrated psychological and exercise intervention for acute whiplash-associated disorders: secondary mediation analysis of a randomized controlled trial. *Pain Rep* 2020; **5**(5): e835.

23.   Sanchez-Roige S, Fontanillas P, Jennings MV, et al. Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry. *Molecular Psychiatry* 2021.

24.   Campos AI, Ngo TT, Medland SE, et al. Genetic risk for chronic pain is associated with lower antidepressant effectiveness: Converging evidence for a depression subtype. *Australian & New Zealand Journal of Psychiatry* 2021: 00048674211031491.

25.   Ferreira GE, McLachlan AJ, Lin C-WC, et al. Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. *BMJ* 2021; **372**: m4825.

26.   Barowsky S, Jung J-Y, Nesbit N, et al. Cross-Disorder Genomics Data Analysis Elucidates a Shared Genetic Basis Between Major Depression and Osteoarthritis Pain. *Frontiers in Genetics* 2021; **12**(1276).

27.	McLean SA, Ressler K, Koenen KC, et al. The AURORA Study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure. *Mol Psychiatry* 2020; **25**(2): 283-96.

28.	Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. *Genet Epidemiol* 2016; **40**(7): 597-608.

29.	Rosoff DB, Smith GD, Lohoff FW. Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders: A Multivariable Mendelian Randomization Analysis. *JAMA Psychiatry* 2021; **78**(2): 151-60.

30.	Brown MA, Xu H, Li Z. Genetics and the axial spondyloarthritis spectrum. *Rheumatology* 2020; **59**(Supplement_4): iv58-iv66.

Figures

Figure 1: Phenome-wide analysis pipeline for eight types of regional chronic pain with 1,492 other complex traits. Genome-wide association studies (GWAS) were performed for chronic back, neck/shoulder, hip, knee, abdominal, facial, headache and widespread pain. These results and publicly available GWAS summary statistics for 1,492 complex traits were uploaded into the Complex Traits Genetics Virtual Lab (CTG-VL), which along with CTG-VIEW was used to perform cross-trait linkage disequilibrium-score (LD-score) regression and latent causal variable analyses to respectively calculate genetic correlations (*rG*) and genetic causal proportions (GCP). The 570 traits with significant GCPs were categorised as per Figures 4–7 (x-axis) and Supplementary Tables S2–S9. This strategy enables the identification and targeting of genetically supported risk and protective factors for chronic pain types in further translationally focused studies.

8 chronic pain GWAS (UK Biobank data)

1,492 complex traits
(GWAS summary statistics)

| SNP | A1 | A2 | BETA | SE | P |

Bivariate linkage disequilibrium score regression (FDR <5%)
— Genetic correlations (*rG*) between 8 chronic pain conditions &
other complex traits (11,936 trait pairs) yielded 5,942 significant *rG*

Latent causal variable analyses (FDR <5%)
of 5,942 *rG* yielded 570 traits pairs with
significant genetic causal proportion (GCP)
GCP > 0.6 — chronic pain condition affects other trait
GCP < -0.6 — trait affects chronic pain condition

Figure 2: Scatterplot matrix showing the genetic correlations (*rG*) between chronic pain and 1,492 complex traits across the eight regional pain types. The genetic correlations were broadly consistent across these types, which indicates the genetic variants specific to each of the 1,492 complex traits had consistent correlations (positive or negative) with the genetic variants associated with each of the chronic pain types. This pattern of results points toward a shared genetic basis common to these chronic pain types, which may partly account for both an increased risk of developing chronic pain (more generally) and its commonly comorbid biopsychosocial traits.

Figure 3: Scatterplot matrix showing 570 significant genetic causal proportions (GCPs) between chronic pain and 1,492 complex traits across the eight regional pain types wherein the LCV analysis method took into account the overlapping samples. There were eight instances where the direction of causal relationships (denoted by GCP > 0·6 or < -0·6) differed between the pain types as detailed in Supplementary Table S18. These included psychological traits (e.g., concerning mania/irritability), family history/social traits, musculoskeletal pathology and other clinical traits. Such differences in the traits' casual directions across pain types may reflect broader multi-directional dynamic relationships (e.g., mania/irritability both impacting & being affected by chronic pain) or may be more specific to regional pain types (e.g., arthrosis contributing to hip pain as joint pathology cf. abdominal pain contributing to arthrosis indirectly, such as via physical inactivity or another pathway). The otherwise broadly consistent direction of causal relationships with complex traits across these common chronic pain types supports a shared biopsychosocial genetic basis.

Figure 4: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of a causal effect upon regional chronic pain types (GCP < -0·6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic back pain, (**B**) neck/shoulder pain, (**C**) hip pain and (**D**) knee pain. A broad range of traits demonstrate evidence of genetic causal effects contributing to an increased risk of chronic pain — notably, psychological traits (e.g., depression on back, neck/shoulder, hip & knee pain), socioeconomic factors (e.g., work-related traits on back, neck/shoulder, hip & knee pain), musculoskeletal pathology (e.g., spondylopathies on neck/shoulder pain), medication use (e.g., dihydrocodeine on back pain) and addiction (e.g., smoking on back, neck/shoulder, hip & knee pain). Other traits had an apparent protective effect against these chronic pain types such as vegetable & dairy consumption and certain work-associated factors (e.g., software programmer/engineer and reduced risk of neck/shoulder pain — Supplementary Table S3 & Supplementary Results 2). BMI: body mass index; COPD: Chronic obstructive pulmonary disease.

Figure 5: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of a causal effect upon regional chronic pain types (GCP < -0·6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic abdominal pain, (**B**) facial pain, (**C**) headaches and (**D**) widespread pain. A broad range of traits demonstrate evidence of genetic causal effects on these pain types, including psychological (e.g., depression, trauma/stress, mania and/or anxiety on headaches, abdominal, facial & widespread pain), gastrointestinal (e.g., colitis on headaches & abdominal pain) and socioeconomic factors (e.g., work-related traits on headaches, abdominal, facial & widespread pain). Other traits had an apparent protective effect against certain chronic pain types such as dairy & cheese consumption (abdominal & widespread pain, respectively) and working as a teacher (abdominal & widespread pain). COPD: Chronic obstructive pulmonary disease; DVT: deep vein thrombosis; ECG: electrocardiogram; GGT: gamma-glutamyl transferase.

A Traits with Effects on Abdominal Pain (GCP < -0.6)

N = 21,285 Cases
N = 239,125 Controls

B Traits with Effects on Facial Pain (GCP < -0.6)

N = 4,037 Cases
N = 239,125 Controls

C Traits with Effects on Headache (GCP < -0.6)

N = 39,283 Cases
N = 239,125 Controls

D Traits with Effects on Widespread Pain (GCP < -0.6)

N = 6,063 Cases
N = 239,125 Controls

Figure 6: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of being affected by chronic pain (GCP > 0·6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic back pain, (**B**) neck/shoulder pain, (**C**) hip pain and (**D**) knee pain. While there are fewer instances of these regional chronic pain affecting other traits than *vice versa* (Fig. 4), these results suggest these chronic pain types have genetic causal effects contributing to increased medication use (i.e., for cholesterol, blood pressure, diabetes or exogenous hormones) and an increased risk of cardiovascular disease (i.e., neck/shoulder pain on ischemic heart disease) along with other disorders (e.g., back pain on depression).

Figure 7: Genetic correlations (*rG*) for traits with significant genetic causal proportion (GCP) estimates indicative of being affected by chronic pain (GCP > 0·6, 5% false discovery rate) are shown across the range of complex trait categories (x-axis). Data are presented for (**A**) chronic abdominal pain, (**B**) facial pain, (**C**) headaches and (**D**) widespread pain. Notably, facial pain showed effects on a wide range of traits including dietary patterns (e.g., reduced muesli, ground coffee), psychological factors (e.g., increased depression, anxiety) and an increased risk of neurological conditions (e.g., mononeuropathies, carpal tunnel syndrome), whereas abdominal pain particularly contributed to an increased risk of cardiovascular disease (e.g., hypertension). Chronic headache had genetic effects contributing to increased analgesic use (i.e., paracetamol, ibuprofen, aspirin) & psychological traits (e.g., depression). Widespread pain affected a range of traits such as an increased risk of surgical complications, analgesic use and disability parking permit use. ECG: electrocardiogram.

A — **Traits Affected by Abdominal Pain (GCP > 0.6)**

N = 21,285 Cases
N = 239,125 Controls

PAIN

Chest pain during physical activity
Hip pain in last month
Infectious & parasitic diseases
Sleep change in context of depression
Cardiovascular disease (sibling)
Hypertension
Blood pressure medication
Arthrosis
Coronary artery disease
No cardiovascular disease
No medications for cholesterol, blood pressure, diabetes, or exogenous hormones
Stopped smoking as health precaution

NO PAIN

B — **Traits Affected by Facial Pain (GCP > 0.6)**

N = 4,037 Cases
N = 239,125 Controls

PAIN

Signal-to-noise-ratio of triplet (right) (hearing test)
Vocational qualification
Respiratory haemorrhage
Infectious & parasitic diseases
Neurological diseases
Anxiety
Mania/irritability
Blue Badge parking permit
Leg fat percentage
Ischaemic heart disease
Nerve, nerve root & plexus disorders
Depression
Hormone-replacement therapy
Serious illness, injury or assault
High cholesterol
Mononeuropathies
Carpal tunnel syndrome
Dozing
Ground coffee
Muesli
Eggs, dairy, wheat, sugar
No major dietary changes in the last 5 years
Cycle
Workplace rarely/never very cold

NO PAIN

C — **Traits Affected by Headache (GCP > 0.6)**

N = 39,283 Cases
N = 239,125 Controls

PAIN

Headache
Paracetamol
Multisite chronic pain
Speech-reception-threshold estimate (right) (hearing test)
Ibuprofen
Depression
Mania/irritability
Aspirin
Facial pain
Talking therapy for depression
No medications for pain relief, constipation, heartburn
No bipolar or depression
Nil pain in last month

NO PAIN

D — **Traits Affected by Widespread Pain (GCP > 0.6)**

N = 6,063 Cases
N = 239,125 Controls

PAIN

Workplace sometimes dusty
Grandchild in household
Chronic neck/shoulder pain
Other arthrosis
Duration of vigorous activity
Paracetamol
Pain in throat and chest
Blue Badge parking permit
Surgical complications
Exercise ECG test traits
Dementia (mother)

NO PAIN

rG

Addiction · Anthropometric · Blood Test · Cancer/Neoplasm · Cardiovascular · Dental · Diet · Ear Nose Throat · Education/Cognition · Eye · Family History · Family/Social · Gastrointestinal · Haematological · Hormones · Immune · Infectious · Medication · Metabolic · Miscellaneous · Musculoskeletal · Neurological · Pain · Psychological · Reproductive · Respiratory · Skin · Sleep · Socioeconomic · Surgical · Trauma/Injury/Stress · Urinary

Figure 8: Causal architecture plots presenting the relationships of various traits with (**A**) chronic back pain, (**B**) neck/shoulder pain and (**C**) hip pain. Each dot represents a genetic correlation (*rG*). The colour of a dot indicates whether the genetic correlation is positive (red) or negative (blue). The x-axis denotes the genetic causal proportion (GCP) estimate and the y-axis denotes the GCP absolute Z-score (i.e., statistical significance). The red dashed line shows the threshold for statistical significance (5% false discovery rate). Traits that have a genetic causal effect on chronic pain are on the left side of the plot (with respect to 0 on the x-axis, GCP < -0·6, black text), while traits causally affected by chronic pain are on the right side (GCP > 0·6, green text). Selected traits are labelled for illustrative purposes — spanning clinical, biological, psychological and socioeconomic measures. Full details of all significant genetic causal relationships are provided in Supplementary Tables S2, S3 & S4. Causal architecture plots for the other regional chronic pain types are presented in Supplementary Figures S1 & S2.

A Chronic Back Pain

B Chronic Neck or Shoulder Pain

C Chronic Hip Pain